KALY - Kali-Extracts Analyst Research Report Featuring New Cannabis Biotechnology Business Set For Release Tomorrow
January 07 2019 - 11:12AM
InvestorsHub NewsWire
KALY - Kali-Extracts Analyst
Research Report Featuring New Cannabis Biotechnology Business Set
For Release Tomorrow
Dallas, TX -- January 7, 2019 --
InvestorsHub NewsWire -- Kali, Inc. (dba/Kali-Extracts)
(USOTC:
KALY) (“KALY”) today confirmed the previously announced analyst
research report featuring the company’s new cannabis biotechnology
business will be released tomorrow. On November 15th, 2018, KALY acquired
NCM Biotech to include a patented cannabis extraction process and
associated intellectual properties consisting of years of
preclinical research studies surrounding a multitude of
applications of cannabis extracts derived from the patented
cannabis extraction process. KALY recently published a summary of results of one of many preclinical
research studies in order to present an example of the
underlying value of Kali-Extracts overall cannabis biotechnology
intellectual properties. KALY is currently a partner in US
Cannabis Health with Puration, Inc. (USOTC:
PURA) and Nouveau (USOTC:
NOUV) which has signed an LOI to explore the development of
cannabis therapies in partnership with Generex Biotechnology
(OTCQB:
GNBT). The analyst report is also expected
to include detail on KALY’s recent $400,000 in new contracts and
the $5 million in revenue expected from KALY’s hemp farming
initiative with NOUV. KALY has recently updated all its financial
reports required by OTCMarkets to satisfy the OTCMarkets “current”
filing standards and anticipates the OTCMarkets site to soon
reflect KALY’s “current” filing status. The analyst research
report scheduled for publication tomorrow on Tuesday, January
8th, 2019 is intended to augment the OTCMarkets
requirements by providing shareholders with an extensive market
analysis of the company’s new business plan and progress toward its
new business plan objects.
To learn more about the KALY visit
www.kali-extracts.com.
Disclaimer/Safe
Harbor:
This news release contains forward-looking statements within the
meaning of the Securities Litigation Reform Act. The statements
reflect the Company's current views with respect to future events
that involve risks and uncertainties. Among others, these risks
include the expectation that any of the companies mentioned herein
will achieve significant sales, the failure to meet schedule or
performance requirements of the companies' contracts, the
companies' liquidity position, the companies' ability to obtain new
contracts, the emergence of competitors with greater financial
resources and the impact of competitive pricing. In the light of
these uncertainties, the forward-looking events referred to in this
release might not occur. These statements have not been evaluated
by the Food and Drug Administration. These products are not
intended to diagnose, treat, cure, or prevent any
disease.
Kali,
Inc.
Frederick Ferri
ir@kali-extracts.com
(214)
210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Sep 2024 to Oct 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Oct 2023 to Oct 2024